These findings suggest that gut microbiota may inhibit tumor progression and enhance the immunotherapy efficacy by downregulating Spp1 expression, with osteopontin potentially serving as a prognosis marker in tumor progression and treatment outcomes. This evidence concerns the gene SPP1 and neoplasm.